Skip to main content
Publications
Sung A, Houghton K, Cornely OA, Neofytos D, Pagliuca A, Capparella MR, Aguado J, Jimenez M, Gheorghe M. Effectiveness, safety, and patterns of real-world isavuconazole use—a retrospective medical record review study of patients with invasive aspergillosis. Poster presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023; April 15, 2023. Copenhagen, Denmark.
Maurer M, Houghton K, Guillet G, Kasujee I, Labrador M, Marsland M, Mcbride D, Rossi O, Stull DE, Valesco M, Chapman-Rothe N. Quality of life and disease control among patients with chronic urticaria in Europe: longitudinal findings from the worldwide prospective observational AWARE study. Poster presented at the 26th EADV Congress; September 13, 2017. Geneva, Switzerland.
Maurer M, Berroa F, Castronuovo A, Ensina LF, Guillet G, Kasujee I, Houghton K, Labrador M, Marsland A, Mcbride D, Rossi O, Valesco M, Stull DE, Chapman-Rothe N. Chronic inducible urticaria (CIndU) in Europe, Central America, and South America: findings from visit 1 of the worldwide AWARE Study. Poster presented at the EAACI Congress 2017; June 20, 2017. Helsinki, Finland.
Maurer M, Guillet G, Houghton K, Kasujee I, Labrador M, Marsland A, Mcbride D, Rossi O, Stull DE, Valesco M, Chapman-Rothe N. Treatment of patients with chronic urticaria in Europe: findings from visit 1 of the worldwide prospective observational AWARE study. Poster presented at the EAACI Congress 2017; June 19, 2017. Helsinki, Finland.
Maurer M, Berroa F, Castronuovo A, Ensina LF, Guillet G, Kasujee I, Houghton K, Labrador M, Marsland A, Mcbride D, Rossi O, Valesco M, Stull DE, Chapman-Rothe N. Healthcare resource utilisation due to chronic urticaria in Europe, South America, and Central America: findings from visit 1 of the worldwide AWARE study. Poster presented at the EAACI Congress 2017; June 18, 2017. Helsinki, Finland.
Maurer M, Houghton K, Stull D, Mcbride D, Janssens N, Heinrichs N, Antonova E, Balp MM, Khalil S. Characterization of responders to omalizumab: exploratory analysis of phase III data from patients with chronic spontaneous urticaria. Poster presented at the European Academy of Allergy and Clinical Immunology Congress; June 13, 2016. Vienna, Austria.